Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease by FAPI PET/CT and 5.0T-MRI
This is a prospective study designed to evaluate the efficacy and safety of Teprotumumab N01 in patients with Thyroid Eye Disease (TED). Eligible patients will receive Teprotumumab N01 and will be assessed using clinical and imaging parameters before and after treatment, with each patient serving as their own control. The primary endpoint is the overall response rate at Week 24.
• Able to comply with the study procedures and voluntarily sign the written informed consent form;
• Male or female subjects aged 18-80 years (inclusive) at screening;
• Body weight between 45 and 100 kg (inclusive);
• Meet internationally recognized diagnostic criteria for TED who are receiving teprotumumab N01 treatment；
• Diagnosed with TED at both the screening and baseline visits;
• Disease duration of less than 9 months